Overview

Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2033-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center